Werewolf Therapeutics, Inc.
HOWL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001785530
No open-market purchases or sales by Werewolf Therapeutics, Inc. insiders were filed in the last 90 days; 46 institutions reported holding it in 13F filings for Q3 2026, worth $11.9M in total; no superinvestor holds it.
Holders of 5% or more of HOWL
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Werewolf Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Balyasny Asset Management LLC | 13G | 6.26%3.04M shares | New | Nov 16, 20261 filing | Nov 16, 2026 | SEC |
| Moll Peter | 13G | 5.20%2.54M shares | New | Sep 21, 20261 filing | Sep 21, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
43 Schedule 13D and 13G filings on Werewolf Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 16, 20266:03 AM ET | Balyasny Asset Management LLCand 4 others | 13G | 6.26%3.04M shares | New | Sep 30, 2026 | SEC |
| Sep 21, 202611:11 AM ET | Moll Peter | 13G | 5.20%2.54M shares | New | Sep 18, 2026 | SEC |
| Jul 2, 20268:26 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 4.10%1.99M shares | −1.90 ppfrom 6.00%Below 5% | Jun 30, 2026 | SEC |
| Jun 26, 20265:39 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 6.00%2.92M shares | −1.50 ppfrom 7.50% | Jun 24, 2026 | SEC |
| Jun 22, 20267:02 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 7.50%3.65M shares | −3.10 ppfrom 10.60% | Jun 17, 2026 | SEC |
| Jun 15, 20268:16 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 10.60%5.14M shares | −2.00 ppfrom 12.60% | Jun 11, 2026 | SEC |
| May 14, 20265:23 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 12.60%6.12M shares | −1.20 ppfrom 13.80% | May 12, 2026 | SEC |
| May 12, 20267:56 PM ET | MPM BioVentures 2014, L.P.and 13 others | 13D/A | 3.80%1.83M shares | −1.60 ppfrom 5.40%Below 5% | May 8, 2026 | SEC |
| May 5, 20267:04 PM ET | MPM BioVentures 2014, L.P.and 13 others | 13D/A | 5.40%2.61M shares | −1.50 ppfrom 6.90% | May 1, 2026 | SEC |
| Feb 11, 20263:46 PM ET | Longwood Fund III, L.P.and 1 other | 13G/A | 3.50%1.68M shares | –Below 5% | Dec 31, 2025 | SEC |
| Jan 16, 20265:36 PM ET | MPM BioVentures 2014, L.P.and 13 others | 13D/A | 6.90%3.37M shares | −1.30 ppfrom 8.20% | Jan 14, 2026 | SEC |
| Dec 29, 20256:59 PM ET | MPM BioVentures 2014, L.P.and 13 others | 13D/A | 8.20%3.98M shares | −1.80 ppfrom 10.00% | Dec 22, 2025 | SEC |
| Dec 3, 20257:04 PM ET | MPM BioVentures 2014, L.P.and 13 others | 13D/A | 10.00%4.87M shares | −1.30 ppfrom 11.30% | Dec 1, 2025 | SEC |
| Nov 17, 20258:00 PM ET | MPM BioVentures 2014, L.P.and 13 others | 13D/A | 11.30%5.48M shares | −2.10 ppfrom 13.40% | Nov 13, 2025 | SEC |
| Nov 6, 20254:29 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 13.80%6.68M shares | −1.20 ppfrom 15.00% | Nov 4, 2025 | SEC |
| Nov 4, 20256:33 PM ET | MPM BioVentures 2014, L.P.and 13 others | 13D/A | 13.40%6.15M shares | – | Oct 31, 2025 | SEC |
| Aug 14, 20254:48 PM ET | PFM Health Sciences, LPand 3 others | 13G/A | 0.90%401.1K shares | −5.60 ppfrom 6.50%Below 5% | Jun 30, 2025 | SEC |
| May 14, 20256:09 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 15.00%6.75M shares | – | May 12, 2025 | SEC |
| Feb 14, 20254:07 PM ET | PFM Health Sciences, LPand 3 others | 13G/A | 6.50%2.91M shares | – | Dec 31, 2024 | SEC |
| Nov 14, 2024 | PFM Health Sciences, LP | 13G/AOld format | – | – | – | SEC |
| Nov 14, 2024 | Bank of America Corp | 13G/AOld format | – | – | – | SEC |
| Nov 13, 2024 | Rubric Capital Management LP | 13G/AOld format | – | – | – | SEC |
| Nov 12, 2024 | Adage Capital Management, L.P. | 13G/AOld format | – | – | – | SEC |
| May 7, 2024 | Ra Capital Management, L.P. | 13D/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Ra Capital Management, L.P. | 13D/AOld format | – | – | – | SEC |
| Feb 14, 2024 | PFM Health Sciences, LP | 13G/AOld format | – | – | – | SEC |
| Feb 13, 2024 | Bank of America Corp | 13GOld format | – | New | – | SEC |
| Feb 12, 2024 | Rubric Capital Management LP | 13G/AOld format | – | – | – | SEC |
| Dec 21, 2023 | Adage Capital Partners GP, L.L.C. | 13GOld format | – | New | – | SEC |
| Feb 10, 2023 | Rubric Capital Management LP | 13GOld format | – | New | – | SEC |
| Jan 17, 2023 | PFM Health Sciences, LP | 13GOld format | – | – | – | SEC |
| Jan 17, 2023 | PFM Health Sciences, LP | 13G/AOld format | – | – | – | SEC |
| Jan 10, 2023 | Ra Capital Management, L.P. | 13D/AOld format | – | – | – | SEC |
| Aug 12, 2022 | Ra Capital Management, L.P. | 13D/AOld format | – | – | – | SEC |
| May 2, 2022 | PFM Health Sciences, LP | 13GOld format | – | New | – | SEC |
| Feb 11, 2022 | Flynn James E | 13G/AOld format | – | – | – | SEC |
| Jun 16, 2021 | Ra Capital Management, L.P. | 13D/AOld format | – | – | – | SEC |
| May 14, 2021 | MPM BioVentures 2014, L.P. | 13DOld format | – | New | – | SEC |
| May 14, 2021 | Longwood Fund III GP, LLC | 13GOld format | – | New | – | SEC |
| May 13, 2021 | Taiho Ventures LLC | 13DOld format | – | New | – | SEC |
| May 10, 2021 | Arkin Moshe | 13DOld format | – | New | – | SEC |
| May 6, 2021 | Ra Capital Management, L.P. | 13DOld format | – | New | – | SEC |
| May 4, 2021 | Flynn James E | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
114 notices from officers, directors and other affiliates planning to sell Werewolf Therapeutics, Inc. shares, newest first.
| Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|
| Jul 6, 20265:19 PM ET | MPM Oncology Innovations Fund, L.P.Shareholder | 21.2K | $7.21K | Jul 6, 202610b5-1 | Merrill Lynch | SEC |
| Jul 6, 20265:19 PM ET | MPM Asset Management Investors BV2014 LLCShareholder | 3.33K | $1.13K | Jul 6, 202610b5-1 | Merrill Lynch | SEC |
| Jul 6, 20265:19 PM ET | MPM Asset Management LLCShareholder | 15.3K | $5.22K | Jul 6, 202610b5-1 | Merrill Lynch | SEC |
| Jul 6, 20265:18 PM ET | UBS Oncology Impact Fund, L.P.Shareholder | 80.1K | $27.3K | Jul 6, 202610b5-1 | Merrill Lynch | SEC |
| Jul 6, 20265:18 PM ET | MPM BioVentures 2014 (B), L.P.Shareholder | 6.46K | $2.20K | Jul 6, 202610b5-1 | Merrill Lynch | SEC |
| Jul 6, 20265:18 PM ET | MPM BioVentures 2014, L.P.Shareholder | 96.9K | $33.0K | Jul 6, 202610b5-1 | Merrill Lynch | SEC |
| Jun 29, 20265:30 PM ET | MPM Oncology Innovations Fund, L.P.Shareholder | 23.2K | $7.51K | Jun 29, 202610b5-1 | Merrill Lynch | SEC |
| Jun 29, 20265:30 PM ET | MPM Asset Management Investors BV2014 LLCShareholder | 3.66K | $1.18K | Jun 29, 202610b5-1 | Merrill Lynch | SEC |
| Jun 29, 20265:29 PM ET | MPM Asset Management LLCShareholder | 16.8K | $5.44K | Jun 29, 202610b5-1 | Merrill Lynch | SEC |
| Jun 29, 20265:29 PM ET | UBS Oncology Impact Fund, L.P.Shareholder | 87.9K | $28.4K | Jun 29, 202610b5-1 | Merrill Lynch | SEC |
| Jun 29, 20265:29 PM ET | MPM BioVentures 2014 (B), L.P.Shareholder | 7.09K | $2.29K | Jun 29, 202610b5-1 | Merrill Lynch | SEC |
| Jun 29, 20265:29 PM ET | MPM BioVentures 2014, L.P.Shareholder | 106.3K | $34.3K | Jun 29, 202610b5-1 | Merrill Lynch | SEC |
| May 28, 20265:04 PM ET | MPM BioVentures 2014, L.P.Shareholder | 244.2K | $119.7K | May 28, 202610b5-1 | Merrill Lynch | SEC |
| May 28, 20265:03 PM ET | MPM BioVentures 2014 (B), L.P.Shareholder | 16.3K | $7.98K | May 28, 202610b5-1 | Merrill Lynch | SEC |
| May 28, 20265:03 PM ET | UBS Oncology Impact Fund, L.P.Shareholder | 202.0K | $99.0K | May 28, 202610b5-1 | Merrill Lynch | SEC |
| May 28, 20265:03 PM ET | MPM Asset Management LLCShareholder | 38.7K | $19.0K | May 28, 202610b5-1 | Merrill Lynch | SEC |
| May 28, 20265:03 PM ET | MPM Asset Management Investors BV2014 LLCShareholder | 8.40K | $4.12K | May 28, 202610b5-1 | Merrill Lynch | SEC |
| May 28, 20265:02 PM ET | MPM Oncology Innovations Fund, L.P.Shareholder | 53.4K | $26.2K | May 28, 202610b5-1 | Merrill Lynch | SEC |
| May 18, 20265:03 PM ET | MPM Oncology Innovations Fund, L.P.Shareholder | 63.5K | $32.7K | May 18, 202610b5-1 | Merrill Lynch | SEC |
| May 18, 20265:02 PM ET | MPM BioVentures 2014, L.P.Shareholder | 290.4K | $149.6K | May 18, 202610b5-1 | Merrill Lynch | SEC |
| May 18, 20265:02 PM ET | MPM BioVentures 2014 (B), L.P.Shareholder | 19.4K | $9.98K | May 18, 202610b5-1 | Merrill Lynch | SEC |
| May 18, 20265:02 PM ET | UBS Oncology Impact Fund, L.P.Shareholder | 240.3K | $123.8K | May 18, 202610b5-1 | Merrill Lynch | SEC |
| May 18, 20265:01 PM ET | MPM Asset Management LLCShareholder | 46.0K | $23.7K | May 18, 202610b5-1 | Merrill Lynch | SEC |
| May 18, 20265:01 PM ET | MPM Asset Management Investors BV2014 LLCShareholder | 10.0K | $5.15K | May 18, 202610b5-1 | Merrill Lynch | SEC |
| May 11, 20264:33 PM ET | MPM Oncology Innovations Fund, L.P.Shareholder | 18.5K | $12.6K | May 11, 202610b5-1 | Merrill Lynch | SEC |
Showing the latest 25. See the HOWL notices from the last 12 months